Patient Related Outcome Measures Dovepress Meta-analysis Provides Evidence-based Interpretation Guidelines for the Clinical Significance of Mean Differences for the Fact-g, a Cancer-specific Quality of Life Questionnaire

Our aim was to develop evidence-based interpretation guidelines for the Functional Assessment of Cancer Therapy-General (FACT-G), a cancer-specific health-related quality of life (HRQOL) instrument, from a range of clinically relevant anchors, incorporating expert judgment about clinical significance. Three clinicians with many years’ experience managing cancer patients and using HRQOL outcomes in clinical research reviewed 71 papers. Blinded to the FACT-G results, they considered the clinical anchors associated with each FACT-G mean difference, predicted which dimensions of HRQOL would be affected, and whether the effects would be trivial, small, moderate, or large. These size classes were defined in terms of clinical relevance. The experts’ judgments were then linked with FACT-G mean differences, and inverse-variance weighted mean differences were calculated for each size class. Small, medium, and large differences (95% confidence interval) from 1,118 cross-sectional comparisons were as follows: physical well-being 1.9 (0.6–3.2), 4.1 (2.7–5.5), 8.7 (5.2–12); functional well-being 2.0 (0.5–3.5), 3.8 (2.0–5.5), 8.8 (4.3–13); emotional well-being 1.0 (0.1–2.6), 1.9 (0.3–3.5), no large differences; social well-being 0.7 (−0.7 to 2.1), 0.8 (−2.9 to 4.5), no large differences. Results from 436 longitudinal comparisons tended to be smaller than the corresponding cross-sectional results. These results augment other interpretation guidelines for FACT-G with information on sample size, power calculations, and interpretation of cancer clinical trials that use FACT-G.

[1]  D. Osoba,et al.  Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. , 2010, Journal of clinical epidemiology.

[2]  Xiao-Hua Zhou,et al.  Statistical Methods for Meta‐Analysis , 2008 .

[3]  P. Fayers,et al.  The clinical significance of adaptation to changing health: A meta-analysis of response shift , 2006, Quality of Life Research.

[4]  D. Cella,et al.  Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[5]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[6]  G. Guyatt,et al.  Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) , 2005, COPD.

[7]  D. Neuberg,et al.  A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. , 2004, Journal of clinical epidemiology.

[8]  Galina Velikova,et al.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Larson,et al.  Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[11]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[12]  L. Fallowfield,et al.  Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy , 2002, British Journal of Cancer.

[13]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[14]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[15]  D H Gustafson,et al.  Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma , 2001, Cancer.

[16]  M. Mehta,et al.  QUALITY OF LIFE ASSESSMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS UNDERGOING AN ACCELERATED RADIOTHERAPY REGIMEN: REPORT OF ECOG STUDY 4593 , 2001 .

[17]  D. Gustafson,et al.  Effect of computer support on younger women with breast cancer , 2001, Journal of General Internal Medicine.

[18]  D. Cella,et al.  Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93). , 2001, Cancer journal.

[19]  M. Kris,et al.  Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[21]  M. King The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 , 1996, Quality of Life Research.

[22]  D. Cella,et al.  The influence of stress management training in HIV disease. , 1996, Nursing research.

[23]  R. Epstein,et al.  Interpretation of quality of life changes , 1993, Quality of Life Research.

[24]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[25]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Cutler,et al.  Variance imputation for overviews of clinical trials with continuous response. , 1992, Journal of clinical epidemiology.

[27]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[28]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[29]  Constantine Gatsonis,et al.  Analysing and Presenting Results , 2010 .

[30]  D. Cella,et al.  Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life , 2002 .

[31]  M. Mehta,et al.  Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. , 2001, International journal of radiation oncology, biology, physics.

[32]  D. Machin,et al.  A clinical model for quality of life assessment in cancer patients receiving chemotherapy. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  D. Cella,et al.  RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. , 1995, International journal of radiation oncology, biology, physics.